FDA Panel Rejects Duchenne Treatment as FTC Targets Hims & Hers Practices
A recent FDA panel's critical vote against a Duchenne drug highlights ongoing scrutiny of digital health practices, particularly Hims & Hers.
Lifestyle trends and health tips
A recent FDA panel's critical vote against a Duchenne drug highlights ongoing scrutiny of digital health practices, particularly Hims & Hers.
The FTC has initiated a lawsuit against Hims & Hers, accusing the telehealth firm of deceptive practices in consumer health data handling.
The end of Medicare drug subsidies is set to elevate out-of-pocket costs for older adults, providing Democrats with a potent campaign issue for the midterms.
The debate over benchmarking clinical AI systems highlights the challenges of interpreting results beyond headlines.
A recent study reveals clinical AI models underperform compared to generalist models, sparking debate in the health AI community.
Prolonged hospitalizations can lead to serious emotional and developmental issues in children due to isolation, highlighting the need for structured support.
In an exclusive interview, astronaut Michael Foale shares his experiences during the 1997 Mir space station collision and the challenges that followed.
The recent Cyclospora outbreak highlights the urgent need for improved food safety measures to protect public health while promoting nutritious diets.
The U.S. has surpassed its 2025 measles case count, signifying a public health crisis driven by falling vaccination rates and significant outbreaks across several states.
An FDA advisory panel endorses peptide accessibility, while Sanofi's insulin pen faces supply shortages, impacting diabetes patients nationwide.
As medical students face new federal loan caps, the barrier to entry in medicine is rising, threatening diversity and access in the healthcare workforce.
A new outbreak of cyclospora, a parasite causing intestinal illness, has been reported with 72 cases identified; investigations are ongoing.
President Trump's nomination of Timothy Westlake for SAMHSA marks a pivotal moment for U.S. mental health and addiction policies.
Eli Lilly's retatrutide shows significant weight loss in obesity trials, but questions linger about its cardiovascular risks despite its promising results.
The White House and HHS gather specialists to establish unified principles for evaluating clinical AI technologies.
Public Citizen petitions the FDA to prohibit direct-to-consumer drug ads, claiming they mislead consumers and prioritize persuasion over education.
As the FDA convenes to discuss peptide accessibility, significant debates arise over safety data and the future of compounding pharmacies.
Federal health officials continue investigations into a cyclospora outbreak linked to Taylor Farms lettuce, despite a false positive test result.
An emergency physician shares a personal tragedy, highlighting the flaws in the U.S. health insurance system regarding mental health treatment.
As wildfires blanket U.S. cities in smoke, the soaring asthma cases reveal significant public health challenges linked to climate patterns.